317 related articles for article (PubMed ID: 17373268)
1. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
Kessler M; Salignac S; Aimone-Gastin I
Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
3. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
4. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
5. [Issues related to iron replacement in dialyzed patients].
Kessler M
Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
[TBL] [Abstract][Full Text] [Related]
6. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
8. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
Easom A
Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
[TBL] [Abstract][Full Text] [Related]
9. Assessing iron status: beyond serum ferritin and transferrin saturation.
Wish JB
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients.
Chang J; Bird R; Clague A; Carter A
Pathology; 2007 Jun; 39(3):349-53. PubMed ID: 17558864
[TBL] [Abstract][Full Text] [Related]
11. Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients.
Kovesdy CP
Adv Chronic Kidney Dis; 2009 Mar; 16(2):109-16. PubMed ID: 19233070
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
13. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?
Kalantar-Zadeh K; Kalantar-Zadeh K; Lee GH
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S9-18. PubMed ID: 17699375
[TBL] [Abstract][Full Text] [Related]
14. Reticulocyte hemoglobin content in hemodialysis patients with acute infection.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2004 Sep; 8(3):257-62. PubMed ID: 15480904
[TBL] [Abstract][Full Text] [Related]
15. [How do we need to maintain the iron status in dialyzed patients treated with erythropoesis stimulating agents].
Kes P; Basić-Jukići N; Jurić I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():54-61. PubMed ID: 20232552
[TBL] [Abstract][Full Text] [Related]
16. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients.
Kim JM; Ihm CH; Kim HJ
Int J Lab Hematol; 2008 Feb; 30(1):46-52. PubMed ID: 18190467
[TBL] [Abstract][Full Text] [Related]
18. Serum transferrin receptor.
Skikne BS
Am J Hematol; 2008 Nov; 83(11):872-5. PubMed ID: 18821709
[TBL] [Abstract][Full Text] [Related]
19. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
20. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
